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Introduction: Cyclooxygenase-2 overexpression may mediate re-
sistance to epidermal growth factor receptor tyrosine kinase inhibi-
tion through prostaglandin E2-dependent promotion of epithelial to
mesenchymal transition (EMT). Suppression of epithelial markers,
such as E-cadherin, can lead to resistance to erlotinib. Prostaglandin
E2 down-regulates E-cadherin expression by up-regulating tran-
scriptional repressors, including ZEB1 and Snail. Furthermore,
E-cadherin can be modulated by matrix metalloproteinases (MMPs)
and tissue inhibitors of MMPs (TIMPs), promoting tumor invasion
and metastasis. Markers of EMT and tumor invasion were evaluated
in patient serum from a phase I clinical trial investigating the
combination of celecoxib and erlotinib in non-small cell lung cancer
(NSCLC) patients.
Methods: Samples from 22 subjects were evaluated. Soluble
E-cadherin (sEC) was evaluated by enzyme linked immunosorbent
assay in patient serum at baseline, week 4, and week 8 of treatment.
Other markers of EMT and angiogenesis were evaluated by enzyme
linked immunosorbent assay, including MMP-9, TIMP-1, and
CCL15.
Results: Serum sEC, MMP-9, TIMP-1, and CCL15 levels were
determined at baseline and week 8. Patients with a partial response
to therapy had a significant decrease in sEC, TIMP-1, and CCL15 at
week 8. In patients who responded to the combination therapy,
baseline MMP-9 was significantly lower compared with nonre-
sponders (p  0.006).
Conclusions: sEC, MMP-9, TIMP-1, and CCL15 levels correlate
with response to combination therapy with erlotinib and celecoxib in
patients with NSCLC. A randomized phase II trial is planned
comparing erlotinib and celecoxib with erlotinib plus placebo in
advanced NSCLC. This study will prospectively assess these and
other biomarkers in serum and tumor tissue.
Key Words: Non-small cell lung cancer, Epidermal growth factor
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(J Thorac Oncol. 2008;3: 117–124)
Lung cancer is the leading cause of cancer death in theUnited States, and for all stages, the 5-year survival for
non-small cell lung cancer (NSCLC) is approximately 15%.1
Targeted therapy with an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) has been shown to
prolong survival in advanced non-small cell lung cancer.2
Although many tumors are insensitive to this treatment, combi-
nation therapy targeting multiple pathways may improve clin-
ical outcome. Combination therapies might delay the onset of
resistance in patients who show an initial response to EGFR
inhibition, or block competing tumor growth pathways in
patients who do not respond to single-agent treatment.3 An
understanding of the mechanisms of action in these combi-
nation-targeted approaches will help us define the mecha-
nisms of resistance.4,5 EGFR and cyclooxygenase-2 (COX-2)
signaling pathways interact to promote tumor proliferation,
invasion, angiogenesis, and resistance to apoptosis.6–9
A potential mechanism of resistance to EGFR TKI in
NSCLC is mediated through an EGFR-independent activa-
tion of the MAPK/Erk signaling pathway by prostaglandin E2
(PGE2), a COX-2 metabolite.6 This pathway involves PGE2-
mediated, protein kinase C-dependent Erk activation that is
not inhibited by otherwise effective doses of the EGFR
inhibitor erlotinib. COX-2 overexpression can also mediate
resistance to EGFR TK inhibition through a mechanism
relating to the PGE2-dependent promotion of epithelial to
mesenchymal transition (EMT).10 Thomson et al. reported
that the suppression of epithelial markers such as E-cadherin
led to resistance to erlotinib.11 In addition, PGE2 down-
regulates E-cadherin expression by up-regulating transcrip-
tional repressors, including ZEB1 and Snail.10 The down-
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regulation of E-cadherin and overexpression of matrix
metalloproteinases (MMPs) and tissue inhibitors of MMPs
(TIMPs) in multiple tumor types have been associated with
increased tumor progression and metastatic potential.12–14
Cadherins are Ca2-dependent cell-cell adhesion mol-
ecules which interact with catenins.15 The E-cadherin–cate-
nin complex plays an integral role in the maintenance of
tissue architecture and cell-cell adhesion.12,15,16 The loss of
E-cadherin has been shown to be associated with increased
tumor invasiveness, metastasis, and poor prognosis in lung
cancer.12,16 Furthermore, MMPs have the ability to cleave
E-cadherin at the cell surface, resulting in the release of a
soluble 80-kDa fragment of E-cadherin.17 Elevated levels of
soluble E-cadherin (sEC) have been described in the blood
and urine of patients with cancer, and increased levels of sEC
have been correlated with decreased survival in NSCLC.18–24
Moreover, both MMP-9 and MMP-2 can be induced by sEC
in lung cancer cells.25
MMPs are proteolytic enzymes that are important in
promoting invasion through the extracellular matrix, and are
involved in tumor invasion and progression.26–28 They can be
induced by PGE2 in NSCLC.29 TIMPs are found in the
extracellular matrix and bind MMPs to inhibit their activa-
tion.30 The balance between MMPs and TIMPs in tumor
tissue plays an important role in tumorigenesis, although
elevated levels of TIMP-1 have been associated with tumor
progression in NSCLC.14,31–33 MMP-2 and MMP-9 are se-
creted molecules that mediate tumor invasion and metastasis
through the degradation of collagen IV.26 Overexpression of
MMP-9 has been associated with a more aggressive tumor
phenotype in NSCLC.31,34–36 Although the importance of
MMP-9 in tumor progression has been well established, the
prognostic significance of MMP-2 in lung cancer has been
variable.37,38
Chemokines are a family of cytokines, subdivided on
the basis of the position of the N-terminus cysteine residue.
They are involved in leukocyte chemotaxis and activation,
and have been associated with the regulation of angiogene-
sis.39–41 Chemokines can be produced by tumor cells, leuko-
cytes, and endothelial cells.42,43 Through interactions with
stromal cells and neoplastic cells, chemokines can potentiate
tumor growth, metastasis, angiogenesis, and immune eva-
sion.44,45 CCL15 is a CC chemokine that induces the recruit-
ment of monocytes and lymphocytes to sites of inflammation
through the chemokine receptors, CCR1 and CCR3.46,47 Fur-
thermore, signaling through CCR1 can modulate MMP ex-
pression and promote tumor proliferation and invasion.48
CCL15 has also been shown to induce angiogenesis and is
elevated in malignancy.49
A phase I clinical trial evaluated the combination of
erlotinib (an EGFR TKI) and celecoxib (a COX-2 inhibitor)
in advanced NSCLC.50 This study established the optimal
biologic dose of celecoxib as 600 mg twice daily, and
demonstrated clinical responses without significant toxicity.
In the patient samples from this trial, we evaluated serum
markers of COX-2 gene expression, EMT, and angiogenesis
to further define a population of patients who are most likely
to benefit from this combination treatment.
PATIENTS AND METHODS
Clinical Study
A phase I, dose escalation trial was conducted in
patients who had disease progression after standard chemo-
therapy for advanced NSCLC at the University of Califor-
nia, Los Angeles (UCLA) Medical Center.50 Three sub-
jects were assigned to each cohort and received erlotinib at
a fixed dose of 150-mg orally daily for two 4-week cycles.
In addition, they received celecoxib in escalating doses per
cohort, starting with 200-mg orally twice daily and in-
creasing by 100-mg doses to 400-mg orally twice daily,
and then increasing by 200-mg doses to 800-mg orally
twice daily. The primary endpoints were evaluation of the
optimal biologic dose of the combination and assessment
of toxicity. Secondary endpoints included biomarker as-
sessment and evaluation of response as determined by
Response Evaluation Criteria in Solid Tumors (RECIST)
Guidelines by computed tomography (CT) at week 8 after
initiation of treatment, and compared with baseline. All
responses were confirmed by repeat CT scans no less than
4 weeks later. The UCLA institutional review board ap-
proved this study protocol, and all patients provided writ-
ten informed consent.
Protein Quantification
Biomarker analysis was blinded with respect to demo-
graphic information and clinical response. Serum and plasma
TABLE 1. Patient Responses
Celecoxib Dose (mg)
Time to
Progression (wk) Mutation Analysis50
Partial response
300 bid 95 Exon 18 2105C3 T
400 bid 36 Exon 18 2156G3 C
400 bid 27 wt
600 bid 34 wt
800 bid 33 del exon 19
8003 400 72 del exon 19
48 del exon 19
Stable disease
200 bid 19 n/a
200 bid 84 wt
600 bid 47 wt
800 bid 9 wt
8003 400 16 wt
Progressive disease
200 bid 10 wt
300 bid 7 wt
300 bid 6 n/a
400 bid 13 wt
600 bid 9 wt
800 bid 9 n/a
8003 400 7 wt
9 n/a
5 wt
bid, twice daily; wt, wildtype; del, deletion; n/a, not available.
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were prepared from peripheral venous blood obtained from
patients at baseline and 4 and 8 weeks after the initiation of study
treatment. Serum was allowed to clot for 1 hour at room
temperature and then centrifuged at 3000 rpm for 10 minutes.
The resulting serum was stored in aliquots at 80°C until
assayed. Plasma tubes were inverted to mix, and were centri-
fuged at 3000 rpm for 10 minutes. The resulting supernatant was
collected and stored in aliquots at 80°C until assayed.
Soluble E-cadherin
Soluble E-cadherin was determined in serum in tripli-
cate by enzyme linked immunosorbent assay using a com-
mercially available kit (R&D Systems, Minneapolis, MN)
following the manufacturer’s instructions.
MMP-9 and TIMP-1
MMP-9 and TIMP-1 were determined in heparin-
plasma using commercially available kits (R&D Systems)
following the manufacturer’s instructions.
CCL15
A Bio-Plex assay was developed to determine the con-
centration of CCL15 in plasma. Commercially available mouse
anti-human CCL15 antibody was covalently linked to a Bio-
Plex bead region 63 with a Bio-Plex amine coupling kit follow-
ing the manufacturer’s instructions (Bio-Rad, Hercules, CA). A
biotinylated goat anti-human CCL15 was used as the detection
antibody. CCL15 was determined in EDTA plasma. The assay
was read in a Bio-Plex 100 (Bio-Rad).
Statistical Analysis
Marker levels were compared between time points (0
versus 4 or 8 weeks) with the paired t test. Markers levels at
individual time points or marker change scores were compared
between pairs of response groups with the two-sample t test and
were compared between the three response groups with one-way
analysis of variance models. All analyses were performed
with S-plus version 6 (Insightful Corp., Seattle, WA), and p
values less than 0.05 were considered significant.
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FIGURE 1. Soluble E-cadherin (sEC) decreases in patients treated with celecoxib and erlotinib who achieve partial response.
sEC was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All pa-
tients at weeks 0, 4, and 8, *p  0.021—decline in patients with PR compared with those with SD and PD. Individual patient
values for (B) patients with PR; (C) patients with SD; and (D) patients with PD.
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RESULTS
Patients
Between August 2003 and June 2005, 22 patients were
enrolled in the phase I clinical trial of combination erlotinib
and celecoxib.50 Serum samples were available from all
patients. Table 1 lists the patients with the clinical response at
the respective dose level.
Decline in Soluble E-Cadherin Correlates
with Response
Based on the ability of COX-2 inhibition to decrease
PGE2-dependent suppression of E-cadherin levels and in-
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FIGURE 2. MMP-9 is lower at baseline and after 8 weeks in patients treated with celecoxib and erlotinib who achieve partial
response. MMP-9 was evaluated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treat-
ment. A, All patients at weeks 0 and 8, *p  0.006—baseline values of patients with PR compared with those with SD and
PD; **p  0.048—decreased values at week 8 in patients with PR compared with those with SD and PD. Individual patient
values for (B) patients with PR; (C) patients with SD; and (D) patients with PD.
TABLE 2. Patient ELISA Data by Response (Average  SD)
Biomarker (ng/ml)
Partial Response Stable Disease Progressive Disease
Week 0 Week 8 p Week 0 Week 8 Week 0 Week 8
Soluble E-cadherin 36  8 27  4 0.021a 39  9 39  11 36  7 36  8
MMP-9 363  143 315  158 0.048a 510  180 495  248 627  291 724  295
0.006b
TIMP-1 402  101 314  38 0.047a 412  79 459  138 415  53 402  47
CCL15 1.7  0.8 1.0  0.4 0.016a 1.7  1.2 2.1  1.8 2.0  1.2 2.0  1.1
a Decline at week 8 in patients with partial response compared with those with stable or progressive disease.
b Baseline value in patients with partial response compared with those with stable or progressive disease.
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crease MMPs in NSCLC,10 we measured sEC in patient
serum at baseline and at weeks 4 and 8 of study treatment.
Baseline levels of sEC in patient serum were not significantly
different between groups with PR, SD, or PD. The sEC levels
at week 8 were significantly lower in patients who achieved
a PR when compared with those with SD and PD (p 0.017;
Figure 1A). In addition, the decline in sEC from baseline to
week 8 was significant in patients with PR compared with SD
and PD (p  0.021; Figure 1A).
Baseline MMP-9 and Change in TIMP-1 Predict
Patient Response
The importance of COX-2 regulation of MMPs and
TIMPs28,29,51 and their role in tumor invasion and metastasis
led us to investigate MMP-2, MMP-9, and TIMP-1 in patient
samples. MMP-9 was lower at baseline in NSCLC patients
treated with celecoxib and erlotinib who had a partial re-
sponse (p  0.006; Figure 2A; Table 2). MMP-9 was also
lower at week 8 in those patients with PR (p  0.048; Figure
2A). In addition, baseline levels of MMP-2 were decreased in
patients who achieved a PR, although the p value was not
significant (data not shown). In patients who had a partial
response, TIMP-1 showed significant reduction at week 8
when compared with patients with SD and PD (p  0.047;
Figure 3A).
CCL15 Reduction Is a Marker for
Partial Response
The capacity of CCR1 and its ligands to modulate
MMPs and promote tumor angiogenesis and invasion45,48
prompted our evaluation of CCL15. CCL15 did not show
significant differences in patients at baseline. In patients with
PR to combination treatment, CCL15 demonstrated a signif-
icant decline from baseline to week 8 compared with patients
with SD and PD (p  0.003; Figure 4A).
DISCUSSION
Evidence that EGFR and COX-2 have related signaling
pathways that can interact to regulate cellular proliferation,
migration, and invasion6–9 has triggered interest in evaluating
the combination of COX-2 inhibition and EGFR inhibition in
multiple malignancies, including NSCLC. The co-expression
of EGFR and COX-2 in human cervical cancer specimens
portended a poor prognosis with increased recurrences.52
When combined COX and EGFR inhibition was evaluated in
a familial adenomatous polyposis (FAP) mouse model, treat-
ment resulted in a 95 to 97% reduction in the incidence of
colonic polyps.53 Furthermore, the combination of an EGFR
TKI with celecoxib either additively or synergistically inhib-
ited growth of squamous cell carcinoma of the head and neck
(SCCHN), induced G1 arrest and apoptosis, and suppressed
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FIGURE 3. TIMP-1 is lower in patients treated with celecoxib and erlotinib who achieve partial response. TIMP-1 was evalu-
ated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks
0 and 8, *p  0.047—decreased levels in patients with PR compared with those with SD and PD. Individual patient values for
(B) patients with PR; (C) patients with SD; and (D) patients with PD.
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endothelial capillary formation.54 The combination of ge-
fitinib and celecoxib at 400-mg twice daily did not improve
responses when compared with gefitinib alone in patients
with NSCLC.55 In addition, the combination of gefitinib and
rofecoxib demonstrated similar disease control to expected
outcomes with gefitinib alone.56 Despite these results, the
combination of erlotinib and celecoxib in escalating doses
with an optimal biologic dose of 600-mg twice daily resulted
in a 33% response rate without significant toxicity.50
Modulation of EMT in NSCLC has been associated
with the sensitivity of tumors to EGFR TKI in NSCLC.11,57
COX-2 plays an important role in EMT through PGE2-
mediated interactions with E-cadherin, MMPs, TIMPs and
chemokines.10,29,51,58 MMP-9 has been shown to be elevated
in lung cancer, and overexpression has been associated with
poor prognosis.31,34–37 Although the evaluation of MMP-9 as
a predictive marker has been limited, in this study, we found
that a low baseline MMP-9 is associated with tumor response
to combined erlotinib and celecoxib therapy in NSCLC.
Decreased posttreatment levels also correlated with patient
response to the combination therapy. In addition, TIMPs have
been associated with a decrease in metastatic potential,28
although multiple studies have identified TIMP-1 as a marker
of adverse outcomes in NSCLC.14,31–33 Our results are con-
sistent with these data. We found that patients with a partial
response to combination erlotinib and celecoxib therapy
had significantly reduced TIMP-1 levels after 8 weeks on
therapy. A decline in markers of EMT and tumor angio-
genesis is associated with improved responses to this
combination therapy.
Elevated levels of circulating sEC have been associated
with poor prognosis in various tumors.18–24 In a recent study,
patients with gastric cancer demonstrated increased levels of
sEC when compared with normal control subjects, and treat-
ment of patients with resectable gastric carcinoma with cele-
coxib resulted in decreased levels of sEC.59 Celecoxib inter-
vention was associated with increased apoptosis and
inhibition of angiogenesis.59 It is hypothesized that a decrease
in sEC in the serum may occur secondary to treatment with
celecoxib, and may be a marker for increased sensitivity to
EGFR TKI therapy. CCL15 is an additional biomarker asso-
ciated with tumor progression and angiogenesis, which dem-
onstrated a decline in our patients with a partial response to
this combination therapy. Our findings that sEC and CCL15
significantly decline in those patients who achieve a partial
response when compared with those with stable or progres-
sive disease suggest that the addition of celecoxib to erlotinib
may increase sensitivity to this therapy.
In this study, we demonstrate that baseline MMP-9
levels correlate with tumor response to the combination of
erlotinib and celecoxib, and this may be useful as a predictive
marker. Other markers of EMT and angiogenesis demon-
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FIGURE 4. CCL15 decreases in patients treated with celecoxib and erlotinib who achieve partial response. CCL15 was evalu-
ated by enzyme linked immunosorbent assay in patient serum at baseline and at week 8 of treatment. A, All patients at weeks
0, 4, and 8, *p  0.016—decline in patients with PR compared with those with SD and PD at week 4; **p  0.003—decline
in patients with PR compared with those with SD and PD at week 8. Individual patient values for (B) patients with PR; (C) pa-
tients with SD; and (D) patients with PD.
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strated a change with treatment, which was associated with
tumor response in patients. Furthermore, we acknowledge
that the associations between patient outcome and tumor
biomarkers in the context of this phase I trial are considered
hypothesis generating. COX-2 inhibition may enhance the
efficacy of EGFR TKI therapy in NSCLC by increasing
tumor sensitivity to this therapy. Additional knowledge of
biomarkers that have baseline values that are associated with
improved outcomes may be useful to identify patients with a
greater likelihood of benefiting from this combined therapy.
A randomized phase II trial investigating the combination of
erlotinib and celecoxib in advanced NSCLC will evaluate
these markers in a prospective manner.
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